Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Clinical Research 9: Early Clinical Studies of Emerging Immunotherapy Approaches

Identification of Class II epitopes specific for IGFBP-2, a tumor antigen in breast and ovarian cancer patients

Kyong-Hwa Park, Doreen Higgins, Corazon De La Rosa and Mary L. Disis
Kyong-Hwa Park
Tumor vaccine group, University of Washington, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Doreen Higgins
Tumor vaccine group, University of Washington, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Corazon De La Rosa
Tumor vaccine group, University of Washington, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary L. Disis
Tumor vaccine group, University of Washington, Seattle, WA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published April 2006
  • Article
  • Info & Metrics
Loading
Proc Amer Assoc Cancer Res, Volume 47, 2006

Abstract

2893

Insulin like growth factor binding proteins are involved in the induction and progression of both breast and ovarian cancers. Studies from our group have shown that patients with cancer can have endogenous IgG antibody immunity directed against IGFBP-2. We questioned whether IGFBP-2 specific CD4+ T cell responses could be identified in cancer patients. Recent studies have demonstrated that CD4+ T cells are necessary to achieve sustained survival and enhanced cytotoxic function of antigen-specific CD8+ T cells. In addition, the generation of an antigen specific CD4+ T cell response, in and of itself, can elicit the generation of CD8+ T cells recognizing the same antigen. Since the generation of antigen-specific CD4+ T lymphocytes depends on specific stimulation by MHC class II-presented antigens, several algorithms for predicting the binding of peptides and HLA-DR have been generated. Some studies have suggested that combining a variety of algorithms may be better than using a single algorithm for prediction of the binding affinity, thus, we developed a scoring system which combines data from 5 publicly available algorithms and identified 14 potential HLA-DR binding peptides derived from IGFBP2. The five algorithms used in this study were SYFPEITHI, Propred, MHC-Thread, Average Binding matrix method, and Rankpep. Twenty IGFBP-2 peptides were identified for each of the 15 most common MHC class II molecules. To predict best binding, we summed the scores that were assigned for different MHC II molecules from the five algorithms (S), and gave a score for the number of MHC class II molecules that the peptide sequence could be predicted to bind to, i.e. promiscuity (N). The final rank scores were assigned by multiplying S and N, and the top 14 peptides were selected. The peptides were then synthesized, and their immunogenicity was interrogated by IFN-γ ELISPOT utilizing peripheral blood mononuclear cells (PBMCs) from volunteer donors and breast cancer patients. Peptide specific T cells could be identified in both volunteer donors and breast cancer patients using 10 of the 14 peptides. Studies are ongoing demonstrating the specificity of the peptide specific T cells for IGFBP-2 protein. The definition of class II epitopes specific for IGFBP-2 will contribute to the development of a vaccine targeting that antigen.

  • American Association for Cancer Research
Previous
Back to top
Cancer Research: 66 (8 Supplement)
April 2006
Volume 66, Issue 8 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Identification of Class II epitopes specific for IGFBP-2, a tumor antigen in breast and ovarian cancer patients
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Identification of Class II epitopes specific for IGFBP-2, a tumor antigen in breast and ovarian cancer patients
Kyong-Hwa Park, Doreen Higgins, Corazon De La Rosa and Mary L. Disis
Cancer Res April 15 2006 (66) (8 Supplement) 679-680;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Identification of Class II epitopes specific for IGFBP-2, a tumor antigen in breast and ovarian cancer patients
Kyong-Hwa Park, Doreen Higgins, Corazon De La Rosa and Mary L. Disis
Cancer Res April 15 2006 (66) (8 Supplement) 679-680;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Poly-TLR agonist polyantigenic vaccine cadi-05 in advanced nonsmall cell lung cancer
  • DOD award: Phase I trial of anti-prostate cancer therapy via anti-PSMA designer T cell autografting
  • Expression of BPSR correlates with breast and prostate tumor progression and invasion
Show more Clinical Research 9: Early Clinical Studies of Emerging Immunotherapy Approaches
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement